Skip to content

CRO

“Evidence-based” development

Design the right study, ensure regulatory success, and turn your clinical data into market access—faster.

A CRO that combines scientific rigor, proprietary technology, and AI


Speed to proof, speed to market

Every week you save on your development plan means market share protected. By co-designing studies with minimal burden, digitizing every step from the e-CRF to statistical analysis, and automating SAS/R programming pipelines, we shorten the time between protocol approval and publication, ensuring your evidence reaches regulators, payers, and prescribers before your competitors’ do.

Regulatory certainty and risk-mitigated execution

A promising molecule can fail simply because of the regulatory process. Our teams have a thorough understanding of the entire regulatory landscape (EMA, FDA, ANSM, CPP, CNIL, Health Data Hub) and select the optimal framework for each study (RIPH 2 vs. 3, MR-001 to 004). The result: submissions accepted on the first try, audits passed from start to finish, and a development path free of avoidable surprises.

Real-World Impact and Patient Engagement

Clinical research no longer stops at the study site—it follows patients where they live. Thanks to hybrid e-cohorts, connected devices, and certified access to national health databases (SNDS), we capture real-world evidence while designing a patient experience that fosters engagement—from the first contact to the final questionnaire—a decisive factor in the success of long-term studies.

Aligning science, operations, and technology to turn every study into a competitive advantage


We help pharmaceutical companies and laboratories identify and generate the clinical, health-economic, and real-world evidence that accelerates the development and market access of their innovations.

Driven by our CRO subsidiary Alsinova, we operate across the entire evidence lifecycle—from pre-clinical research to clinical trials and real-world evidence (RWE) studies—utilizing flexible collaboration models (Consulting, FSP, and Full Service).

Our teams support life sciences stakeholders in the most demanding fields, notably oncology, rare diseases, immunology, and metabolic diseases, by combining scientific expertise, access to health data, and artificial intelligence to accelerate evidence generation while guaranteeing quality, compliance, and strict adherence to timelines.

26

Countries covered

2 017

SNDS-accredited engineering firm

7

Life sciences segments covered

Study Co-design, Regulatory Strategy & Early Access
  • Study co-design and data source strategy: we design low-burden studies with the patient’s voice integrated right from the protocol, providing a transparent assessment of every mobilizable data source (investigator sites, patients, connected devices, SNDS).
  • Regulatory pathways and submissions: we select the optimal framework for each project (RIPH 2 vs. RIPH 3; MR-001 to 004 vs. CNIL authorization) and lead the entire preparation process, from pre-synopsis to regulatory review (CPP, ANSM, CNIL, Health Data Hub), including scientific advice and patient association involvement.
  • Early and compassionate access (AAP/AAC): end-to-end management, from regulatory navigation with the FDA, EMA, and national authorities to safety and efficacy monitoring, to bring innovative treatments to patients with unmet medical needs.
Clinical Operations & Real-World Evidence (RWE) Studies
  • Clinical operations and risk-based monitoring: one dedicated Site Manager per site, from selection to closure, supported by a CRM-type system. Our ARC teams in Europe and North America work on daily analytics specific to each study, which continuously identify data density discrepancies and high-risk practices.
  • Real-world studies and hybrid e-cohorts: prospective e-cohorts, registries, ambispecific and retrospective designs, and hybrid protocols linked to national health databases. Our proprietary platform maintains patient engagement over many years, whereas large cohorts lose their evidence due to attrition.
  • Medical writing and publishing: protocols, eCRFs, and ePROs designed by cross-functional teams of medical writers and digital experts. Documents designed to move through the regulatory review process more quickly, generate analyzable data sooner, and be converted into abstracts accepted for international conferences.
Data, Biostatistics, Safety Monitoring & AI
  • Data management, biostatistics, and AI-accelerated analytics: from pre-clinical omics pipelines to CDISC-compliant databases (CDASH, SDTM, ADaM), the entire chain is secured from baseline lock to analysis. Highly automated SAS and R programming, and AI-assisted SDTM mapping.
  • SNDS, EGB, and population-scale evidence: accredited study office since 2017 (RERC171027), member of the AFCROs Real World Data group and REDSIAM. The first study office in France to have led the simplified access procedure to the EGB in less than 15 days. We link National Health Insurance data to your prospective studies.
  • Pharmacovigilance and regulatory affairs: a global team covering the entire product lifecycle (SDEA, case processing, etc.) and MA management across the pharma, medical device (MD), IVD, cosmetic, and food supplement segments. RegIntel, our proprietary solution, automates AE processing and compliance tracking.

Our Quotes


Hervé Servy

Hervé Servy

Chief Operating Officer – Sanoïa

“In the life sciences, a study’s performance no longer depends solely on its execution. It is shaped from the design stage onward by aligning medical, regulatory, technological, and health economic considerations, and by maintaining that alignment through to evidence generation. Only under these conditions can a CRO become a true partner to the sponsor.”

Our engagements


Our Research


At a time when development costs are rising and regulatory expectations are becoming more stringent, competitiveness in the life sciences hinges on a single capability: generating the right evidence faster than the market moves.

Our Articles


Five Best Practices for Implementing a Clinical Data Fabric (CDF)

A Clinical Data Framework (CDF) is a type of data architecture that enables pharmaceutical companies, medtech firms…

How digitalization improves clinical data management practice

Clinical trials generate a massive amount of data. In most cases, the challenge lies less in the volume of data to be processed than in its diversity.

Facilitate the mapping of data to the SDTM format through standardization and AI.

Our clients are mid-to-large size healthcare companies based in Europe, willing to fully embrace digital technologies.